Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Phase 2 Study Of IDH 1/2 Inhibitor Vorasidenib In Patients With IDH2-Mutated Intrahepatic Cholangiocarcinoma

10 de noviembre de 2026 actualizado por: M.D. Anderson Cancer Center

To find the recommended dose of vorasidenib that can be given to participants with IDH2-mutated iCCA.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

Primary Objectives and Endpoints To evaluate the safety and efficacy of vorasidenib in participants with IDH2-mutated iCCA.

Primary endpoints for the study will be the evaluation of dose-limiting toxicities (DLTs) and landmark progression-free survival (PFS).

Tipo de estudio

Intervencionista

Inscripción (Estimado)

26

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • UT MD Anderson Cancer Center
        • Contacto:
        • Investigador principal:
          • Milind Javle, MD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Eligibility Criteria

  1. Patients with diagnosis of unresectable or metastatic iCCA (confirmed by treating clinician) who have received at least one first-line standard of care systemic therapy for iCCA.

  2. Patients must have received a standard first-line therapy (as per NCCN guidelines) for cholangiocarcinoma/ biliary cancer

  3. Presence of an IDH2 mutation confirmed by laboratory testing using validated methods, such as polymerase chain reaction (PCR) or next-generation sequencing (NGS).

  4. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm (≥2 cm) by chest x-ray or as ≥10 mm (≥1 cm) with CT scan, MRI, or calipers by clinical exam.

  5. Age ≥18 years.

  6. ECOG performance status ≤2 (Karnofsky ≥60%,).

  7. Patients must have adequate organ and marrow function as defined below:

    • absolute neutrophil count ≥1,000/mcL
    • platelets ≥75,000/mcL
    • total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)
    • AST(SGOT)/ALT(SGPT) ≤2.5 × institutional ULN
    • Creatinine ≤ institutional ULN
  8. For Participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable

  9. Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For Participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.

  10. Participants with a prior or concurrent malignancy whose natural history or treatment does not interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

  11. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, Participants should be class 2B or better.

  12. The effects of vorasidenib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:

    • Postmenopausal (no menses in greater than or equal to 12 consecutive months).
    • History of hysterectomy or bilateral salpingo-oophorectomy.
    • Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
    • History of bilateral tubal ligation or another surgical sterilization procedure.
  13. Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

  14. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and not donate sperm for the duration of study participation, and 4 months after completion of vorasidenib administration.

  15. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

  1. Prior treatment with an IDH inhibitor.

  2. Participants who have had chemotherapy or radiotherapy within 3 weeks prior to entering the study.

  3. Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 2 with the exception of alopecia.

  4. Participants who are receiving any other investigational agents.

  5. Concomitant use of strong CYP3A4 inducers or inhibitors, or medications with potential for significant drug-drug interactions with vorasidenib as detailed in the prescribing information (https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf).

  6. Participants with active brain metastases. The investigator(s) must state a medical or scientific reason if Participants who have brain metastases will be excluded from the study.

  7. History of allergic reactions attributed to compounds of similar chemical or biologic composition to [list out Agent(s)] or other agents used in study.

  8. Examples of such agents or substances include those that interact through the CYP450 isoenzyme system or other sources of drug interactions (e.g., P-glycoprotein). Specifically excluded substances may be listed below and presented as an appendix. If appropriate, the following text concerning CYP450 interactions may be used or modified.

    Note: This must account for all agents to be used in this study, including commercial agents. Please refer to the FDA product labels for all commercial agents and include information on prohibited concomitant medications in all applicable sections of the protocol.

  9. Participants with uncontrolled intercurrent illness (Indicate clearly what type or extent)

  10. Human immunodeficiency virus (HIV)-infected Participants are excluded, except those on effective ART with undetectable viral load, who are eligible.

  11. Participants with psychiatric illness/social situations that would limit compliance with study requirements.

  12. Pregnant women are excluded from this study because vorasidenib is agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with vorasidenib, breastfeeding should be discontinued if the mother is treated with vorasidenib. These potential risks may also apply to other agents used in this study.

  13. The investigator(s) must state a medical or scientific reason if Participants who are cancer survivors will be excluded from the study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Safety Run-In/Expansion

Treatment with Vorasidenib (PO) Q4W

Give by po

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Safety and adverse events (AEs
Periodo de tiempo: Through study completion; an average of 1 year.

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 6.0

Through study completion; an average of 1 year.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Milind Javle, MD, UT MD Anderson Cancer Center

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

29 de abril de 2027

Finalización primaria (Estimado)

1 de enero de 2029

Finalización del estudio (Estimado)

1 de enero de 2031

Fechas de registro del estudio

Enviado por primera vez

10 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Publicado por primera vez (Actual)

16 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • 2026-1152
  • NCI-2026-08423 (Otro identificador: NCI-CTRP Clinical Registry)

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .